APA (7th ed.) Citation

Fujisawa, T., Masuda, N., Yamamoto, N., Iwata, H., Bando, H., Aruga, T., . . . Toi, M. (2021). 142P Long-term follow-up of neoadjuvant dual anti-HER2 therapy with trastuzumab and lapatinib plus paclitaxel, with or without endocrine therapy for HER2-positive primary breast cancer: Neo-LaTH (JBCRG-16) study. Annals of Oncology, 32, S422. https://doi.org/10.1016/j.annonc.2021.08.423

Chicago Style (17th ed.) Citation

Fujisawa, T., et al. "142P Long-term Follow-up of Neoadjuvant Dual Anti-HER2 Therapy with Trastuzumab and Lapatinib Plus Paclitaxel, with or Without Endocrine Therapy for HER2-positive Primary Breast Cancer: Neo-LaTH (JBCRG-16) Study." Annals of Oncology 32 (2021): S422. https://doi.org/10.1016/j.annonc.2021.08.423.

MLA (9th ed.) Citation

Fujisawa, T., et al. "142P Long-term Follow-up of Neoadjuvant Dual Anti-HER2 Therapy with Trastuzumab and Lapatinib Plus Paclitaxel, with or Without Endocrine Therapy for HER2-positive Primary Breast Cancer: Neo-LaTH (JBCRG-16) Study." Annals of Oncology, vol. 32, 2021, p. S422, https://doi.org/10.1016/j.annonc.2021.08.423.